| |
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
Today’s Big NewsJun 26, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| By Zoey Becker Hervé Hoppenot is retiring after 11 years spent growing Incyte from a one-drug operation to a competitive commercial drugmaker. His successor, Bill Meury, comes with a track record of dealmaking. |
|
|
|
By Gabrielle Masson Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 million in biobucks up for grabs per target. |
By Kevin Dunleavy The CDC’s Advisory Committee on Immunization Practices has blessed Merck’s new respiratory syncytial virus shot Enflonsia, but the decision was hardly resounding from Robert F. Kennedy Jr.’s newly formed panel of advisors. |
By Angus Liu Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset. |
|
The biologics development and manufacturing sector has long been at the forefront of innovation, consistently driving therapeutic advancements for a wide array of complex diseases. While demand has never been greater, there are still many technical challenges. This valuable resource uncovers how to navigate today’s top obstacles. Download now.
|
|
By James Waldron Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis study, while still showcasing the asset’s weight loss potential. |
By Kevin Dunleavy Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has demonstrated its effectiveness in another group of patients with the bleeding disorder. |
By Conor Hale Medtronic said it received 33 reports of serious injuries related to the device. |
By James Waldron Hummingbird Bioscience could one day feather its nest with up to $290 million if its decision to license a phase 2-ready cancer drug to Percheron Therapeutics pays off. |
By Nick Paul Taylor Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo. Still, the biotech pointed to other outcomes to make the case for the molecule. |
By Fraiser Kansteiner A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal government is back for more. |
By Andrea Park Another of Publicis Groupe’s health-focused agencies is shaking up its executive team this week, as Saatchi & Saatchi Wellness announced Wednesday the appointments of three new leaders. |
By Conor Hale The plan is to employ the Apple Vision Pro headset for live viewing of colonoscopies and layer in AI highlights within the physicians’ field of view. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
QPS leverages a combination of clinical and regulatory expertise, exceptional data scientists, and AI to deliver RWE studies that support accelerated drug development for biotech clients. Learn More.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
